Trials / Completed
CompletedNCT00289614
Patients With Renal Impairment and Diabetes Undergoing Computed Tomography (CT)
Patients With Renal Impairment and Diabetes Undergoing Computed Tomography
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 350 (estimated)
- Sponsor
- Bracco Diagnostics, Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to compare the incidence of contrast induced nephrotoxicity following the administration of Isovue (iopamidol) or Visipaque in diabetic patients with moderate to severe chronic renal impairment undergoing clinically indicated contrast enhanced multidetector computed tomography (MDCT). Serum creatinine will be measured before and up to 48-72 hours post dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Iopamidol 370 mgI/dL |
Timeline
- Start date
- 2006-01-01
- Completion
- 2007-04-01
- First posted
- 2006-02-10
- Last updated
- 2008-01-07
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00289614. Inclusion in this directory is not an endorsement.